FDA Drug Safety Communication: Using codeine cough-and-cold medicines in children

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: FDA Drug Safety Communication: Using codeine cough-and-cold medicines in children

	July 2015 http://www.fda.gov/womens FDA evaluating the potential risks of using codeine cough-and-cold medicines in children The U.S. Food and Drug Administration (FDA) is investigating the possible risks of using codeine-containing medicines to treat coughs and colds in children under 18 years because of the potential for serious side effects, including slowed or difficult breathing. We are evaluating all available information and will also consult with external experts by convening an advisory committee to discuss these safety issues. We will communicate our final conclusions when our review is complete.  Parents and caregivers who notice any signs of slow or shallow breathing, difficult or noisy breathing, confusion, or unusual sleepiness in their child should stop giving their child codeine and seek medical attention immediately by taking their child to the emergency room or calling 911. Read Drug Safety Communication Please share this update with your network, members, constituents, and community. FDA Office of Women’s Health 10903 New Hampshire Avenue WO32 - Room 2333 Silver Spring, MD 20993-0002 301-796-9440

---

Subscriber Services:
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420